Colorectal cancer (CRC) is one of the three most common cancer types worldwide and is responsible for more than 10% of all cancer deaths in men and women, respectively[1]. Pulmonary metastases occur in 15% of metastatic CRC (mCRC) patients, and the lung is the second site of metastases occurrence after the liver[2]. Many therapeutic options are available, ranging from target therapies to surgical resection. Pulmonary metastases surgery, when feasible, is the best treatment showing a 5-year overall survival (OS) between 25% and 35%[3]. In particular, lung metastasectomy has a long history, and since the 1950s, specific indications were provided with the aim of identifying patient subsets who might benefit from surgical resection[3]. The management of mCRC patients with lung disease requires a multidisciplinary approach and the evaluation of several factors related to patient and tumor characteristics might affect prognosis. The lack of strong scientific evidence makes choosing the most appropriate strategy challenging. National and international guidelines recommend radical resection of lung metastases whenever possible and recommend perioperative or postoperative chemotherapy by evaluating prognostic factors on a case-by-case basis. One of the most considered parameters is the number of lung metastases to predict therapy type, which might be systemic in the case of multiple spreading or ablative in limited or oligo-metastatic disease. However, multiple ablative approaches are currently available and consist of surgical resection, stereotaxic radiotherapy, crio or radiofrequency ablation.
Prognostic factors in single lung metastasis are still undefined, and a better stratification could be fundamental in identifying the most appropriate diagnostic and therapeutic approach.
The aim of this review is to describe possible treatments and survival outcomes in patients with single lung metastases from CRC to support physicians’ decision-making on how best to manage these patients.
CRC represents the second most common cancer in females and the third in males[4] and almost 700000 people die every year due to CRC, making it the world's fourth most deadly cancer (after lung, liver and stomach cancer)[5]. In 2020, there were approximately 150000 new cases of CRC in the United States[6]. Despite these relevant numbers, the incidence of CRC decreased from 60 per 100000 people in the 1970s to 38 in 2016[7]. This evidence is substantially attributable to screening programs, early CRC detection and better treatment modalities. Although the implementation of screening allows early diagnosis of CRC, approximately 25% of CRC patients have distant metastases at diagnosis[8,9]. Among patients with mCRC, the lung is the most common extra-abdominal site of metastases[10]. In particular, lung metastases occur in about 10%-30% of all patients diagnosed with advanced disease[11], but only 10% are isolated without liver metastasis[12].
Then the wood-pigeons said, “Coo, coo; we have seen little Kay. A white fowl16 carried his sledge17, and he sat in the carriage of the Snow Queen, which drove through the wood while we were lying in our nest. She blew upon us, and all the young ones died excepting us two. Coo, coo.”
In a 30-year population-based study, synchronous lung metastases were seen in approximately 10% of patients often associated with liver metastases, while synchronous isolated lung metastases were only seen in around 3% of patients and most often in rectal cancer patients[10].
In a systematic analysis performed by Parnaby
[13], the incidence of pulmonary metastases from rectal cancer during initial staging ranged from 10%-18%. For colon cancer patients, the incidence of pulmonary metastases at the time of initial staging ranged from 5%-6%. Tan
[12] analyzed data from a large cohort in Singapore (754 patients over 4 years) and estimated that isolated pulmonary metastases (no other evidence of metastases elsewhere) develop at any point in the follow-up period, not just at initial staging. The incidence of isolated pulmonary metastases in patients with rectal cancer
colon cancer was 12%
6%.
Since the introduction of spiral computed tomography (CT) scanners, smaller lesions can be detected at the time of preoperative staging. The significance of indeterminate lung lesions is an open question as the presence of pulmonary metastases during staging CT could change the treatment pathway. Several studies concluded that only a small rate of indeterminate lung lesions are metastases[14]; in approximately 20%-30% of CT scans for CRC staging, indeterminate lesions have been found, but only 10%-20% were malignant[14,15].
Grossmann, in an observational cohort study[16], included preoperative staging CT of the chest and abdomen in 200 patients with CRC, 5 patients had pulmonary metastases and 50 (25%) had indeterminate nodules (8 metastases diagnosed as true at follow-up). Considering the low incidence of pulmonary metastases and the relative minimal impact on treatment plans, the authors concluded that routine staging based on chest CT in CRC patients is not recommended[16], and the presence of indeterminate lung nodules should not delay surgery for CRC[14].
Even if some radiological characteristics can suggest the metastatic nature (well-circumscribed nodules, smooth margins, subpleural or peripheral localization, cavitation or vascular sign), no pathognomonic radiographic features exist that discern metastasis from a primary lung cancer or from benign processes. When multiple nodules are present, the probability of metastatic disease increases significantly. High-resolution helical CT is better than conventional CT as it detects approximately 20%-25% more nodules, as small as 2 to 3 mm[17]. Similarly, an isolated pulmonary nodule presenting as a subsolid lesion (so called ground-glass opacity) are highly suggestive of a primary lung tumor rather than metastatic lesion[18]. In addition, if a single pulmonary nodule is detected during oncological follow-up in a patient with previous CRC history, the probability of malignancy is higher. In a retrospective cohort study including 1104 patients resected at a single institution from 1989 to 1998, 63% of patients with a resected solitary nodule and without previous cancer, 82% with a history of lung cancer, and 79% with a history of extra-pulmonary cancer, had a malignant tumor[19].
In particular, the probability that a solitary pulmonary nodule was cancer ranged from 67% for nodules ≤ 1 cm to 91% for nodules > 3 cm in patients with prior malignancy. Lung cancer was more common than metastasis if the nodule was > 3 cm.
To clarify the significance of indeterminate nodules in patients with CRC discovered by traditional radiological imaging, fluorodeoxyglucose (FDG)-positron emission tomography (PET)-CT has a valuable role as it improves staging accuracy to select the appropriate treatment. A study by Jess
[20] demonstrated that the discovery of an indeterminate lung nodule during staging by means of a CT scan, was identified as a malignant nodule following a PET-CT scan three months after the previous CT scan. However, PET has limited sensitivity for lesions < 1 cm in size, with a sensitivity of 0.405 for metastases of 5-7 mm in diameter to 0.784 for lesions of 8-10 mm and to 0.935 for lesions measuring 11-29 mm in diameter[21]. Moreover, an 18F-FDG PET-CT scan is not particularly effective in distinguishing primary lung tumors from solitary pulmonary metastases and CRC[22], considering that these diseases usually present with an increased metabolic uptake. On the contrary, a negative PET scan result should not be the only determinant when planning the strategy of care. Indeed, if a lung nodule grows, even if the PET scan is negative, surgical resection can be indicated for diagnostic and potentially therapeutic purposes.
The main value of PET is its high level of sensitivity in the detection of extra-thoracic disease. If on the one hand, resection for lung metastasis should not be performed, unless all known disease areas are being treated, on the other hand, positive extra-thoracic or mediastinal uptake is insufficient to exclude a patient from metastasectomy. All suspicious extra-thoracic sites should be investigated, if possible also with a biopsy, before surgery.
Different prognostic factors have been analyzed in patients with lung metastases from CRC, including factors linked to primitive tumors but also patients’ oncological history. The main considered prognostic factors are reported in Table 1, even if detailed analyses in patients with single metastasis are very rare.
Finally, carcinoembryonic antigen (CEA) could be a useful marker to detect metastasis and recurrence, and current guidelines recommend following up serum CEA regularly to detect recurrent disease. An increased CEA level could be indicative of mCRC when a pulmonary nodule is detected. Moreover, baseline CEA could be a good prognostic factor after recurrence[23].
Colorectal neoplasms are the most common epithelial lesions for which pulmonary metastasectomy is indicated and they are the only type of primary metastatic cancer of the lungs in which the survival advantages of pulmonary metastasectomy were demonstrated in a randomized clinical trial, despite being limited by several pitfalls and controversies[24].
Two years ago I had a best friend, we grew so close together. I always had had a crush on(,) him, but I figured that it would be better if we stayed friends. Every touch was cherished1 and every moment I spent with him was cherished more. Everybody told me that it was a simple crush and I would be over him in no time. Those were the longest fifteen months of my life so far.
In current clinical practice, pulmonary metastasectomy, in the context of controlled primary tumor sites, is performed with curative intent, as favorable survival has been reported in CRC patients with complete resection of pulmonary metastases by several authors[25-28]. This seems to be particularly evident in single pulmonary metastases where complete resections are achievable. The surgeon's approach should be modulated considering various parameters pertaining to safety margins including local growth properties, size, spread and location of lung metastases. It clearly emerges that a strategy of care should be discussed on an individual, interdisciplinary basis to offer the best possible oncological and surgical results and to maximize long-term patient survival rates.
As reported above, a limited subset of CRC patients may benefit from a potentially curative lung metastasectomy[29], provided some strict criteria are met:
Radicality: All pulmonary lesions are technically resectable. In single pulmonary metastases radicality is always achievable, despite the fact that it sometimes requires an anatomical resection instead of the most commonly performed non-anatomical wedge resection.
Feasibility: Patients might tolerate pulmonary resection following evaluation of pulmonary reserve.
Oncological control of disease: The primary CRC site is controlled and extra-thoracic lesions are undetectable (with the exception of resectable liver metastases). General disease control is imperative before performing lung resection and often re-staging imaging (whole body CT-scan or PET-CT scan) is recommended.
Despite that, the presence of solitary pulmonary metastases from CRC ideally represents the best scenario for surgery, and the patient’s oncological history needs to be carefully evaluated during a multidisciplinary tumor board encompassing the presence of a thoracic surgeon. In particular, the timing of lung metastases appearance (synchronous with primary CRC, after liver metastasis treatment, recurrence of lung metastases) should always be considered in the treatment plan.
For many decades, radical pulmonary resection
thoracotomy has been a standard treatment for metastatic lung tumors[30], even though mini-invasive approaches have been proposed in the last two decades[31,32], resulting in likely similar clinical survival outcomes. However, robust evidence-based data are lacking and no focused analysis has been conducted investigating only CRC patients with solitary pulmonary metastases. A recent metaanalysis performed by Meng
[32] compared the results of 8 studies and showed that no difference between video-assisted thoracic surgery (VATS)
open thoracotomy metastasectomy were detected in terms of the OS rate (HR, 0.72; 95%CI: 0.50-1.04) or the recurrence-free survival rate (HR, 0.79; 95%CI: 0.59-1.08). Nevertheless, as correctly remarked by the authors, further large prospective studies are needed to identify the indications for VATS in patients with pulmonary metastases. In addition, it is logical to assume that in solitary pulmonary lesions VATS procedures are more frequently feasible compared with multiple pulmonary lesions, as completeness of resection it is more easily achieved. Based on these assumptions, we can state that VATS pulmonary resection may be efficacious in most CRC patients with single pulmonary metastases, when two conditions substantially coexist: (1) experience with minimally invasive pulmonary resection; and (2) patient selection (especially anatomical location of the lesion); the interval from chest CT-scan and surgery should be limited to avoid occult pulmonary lesions during VATS procedures.
Concerning the extension of resection, a parenchymal-sparing approach is always recommended for the following reasons: (1) The extent of resection is not related to the survival outcome; (2) Wedge resection seems to be associated with a better short-term outcome compared to segmentectomy/ lobectomy[32,33]; and (3) Sparing lung parenchyma is pivotal for eventual re-do surgery. However, segmentectomy seems to be associated with lower relapse rates compared to wedge resection, due to a lower resection-margin recurrence[33]. Therefore, when technically feasible, wedge resection or segmentectomy should be preferred to lobar resection and surgeons should attempt this strategy as much as possible.
How I wish a colorful bundle of fresh wildflowers could reflect the beauty of your way with children-the constant patience and nurturing6, the gentle encouragement. A keepsake basket laden7 with soothing8 soaps and bath oils would eventually serve only as a common gift were its sturdy, woven walls not filled to overflowing9 with examples of the individual ways you have touched the lives of your students.
With regard to the surgical technique for nodule resection, the standard method consists of stapler use; however, laser-assisted lung resection has emerged as an alternative option. Regardless of the laser type adopted, this technique demonstrated similar early and long-term results after pulmonary metastasectomy[34], and is also associated to a lower local recurrence rate in some studies compared with stapler resection[35]. Moreover, laser resection may avoid the need to perform a lobectomy in selected cases[36] and, owing to recent technological improvements, laser-assisted lung resection may be feasible (especially in single pulmonary metastases) even
uniportal VATS (the least invasive approach available today)[37].
Approximately 70% of CRC metastases are unresectable and radiotherapy represents a very promising and rapidly evolving non-invasive treatment modality, particularly stereotactic body radiation therapy (SBRT)[1]. In fact, SBRT can potentially be equally effective and less toxic than surgery, especially in elderly patients and those with important comorbidities[38]. In detail, SBRT is a treatment technique with very sharp radiation dose gradients, which allows the delivery of high doses per fraction in a few days (less than or equal to 8), corresponding to consistently higher biologically equivalent doses in comparison with standard radiotherapy resulting in highly targeted treatment, with good surrounding healthy organ sparing, relative non-invasiveness and good tolerance.
The goal of CRC metastasectomy is to obtain a R0 resection[1,2], and there is little evidence regarding the prognostic role of the resection margin distance. Indeed, only Davini
[76] reported a significant difference in survival when comparing a free resection margin >
> 2 cm, while in other studies it was not investigated or did not show statistical significance[61,62]. However, considering the integrated treatments that may follow surgical resection, it is possible that the resection distance did not influence survival when a complete resection was performed.
On the other hand, mediastinal lymphadenectomy during lung metastasectomy is infrequently performed, and is one of the most common missing analyzed variable[68].
In the setting of oligometastatic disease, mainly involving lung and liver, a surgical approach can be considered, especially when the pulmonary parenchyma is minimally involved. Analysis of the liver in a survey registry evaluated 9619 mCRC patients divided into three groups: group 1 (9185 patients with liver-only disease, radically resected), group 2 (149 patients with liver and lung disease, both radically resected), and group 3 (285 patients with liver and lung disease, only liver resected). The 5-year OS was similar for patients in group 1 and 2 (51.5% and 44.5%, respectively) and worse for patients in group 3 (14.3%) (
= 0.001)[56]. Thus, these findings confirm the importance of radical surgery of both liver and lung metastases, when achievable.
In terms of results, Filippi
[40] demonstrated similar OS outcomes between SBRT and surgery (89%
96% at 1 year and 77%
82% at 2 years,
= 0.134) in 142 patients with lung metastases, including 78 (55%) with single metastases. Moreover, a higher rate of local and distant recurrences occurred in the SBRT cohort, whereas a similar death rate was demonstrated. This retrospective study also showed a worse prognosis in terms of progression-free survival (PFS) in the SBRT cohort, but it cannot be excluded that this was influenced by different follow-up protocols and different sample sizes.
58. They lived happily ever afterward: The Grimms changed the story considerably138 to try to justify139 the father s redemption and ability to live happily ever after. However, many critics, such as Hans Dieckmann, find the ending disturbing and even unethical. The father, who was too weak to resist the evil suggestion of his wife and with her abandoned the children in the forest, is not only not punished for his highly immoral140 way of acting141 but even gets to enjoy the treasures the children bring back (Dieckmann 1986). Also note that part of their happiness centers on their acquisition of material wealth.Return to place in story.
Kobiela
[39] performed a systematic review of oligometastatic patients (average number of lesions per patients = 1.5) and showed that SBRT offers high local control rates (up to 90%) and satisfactory OS rates (up to 70% at 2 years) with a PFS of 9 to 34.4 mo and a relatively low toxicity burden. These data are similar to those obtained by Franzese
[44], who showed a local control rate of 95% at 1 year and 73% at 3 years in 270 patients with a maximum of 5 lung metastases, 59% of the patients had a single disease location. However, disease progression outside the irradiation field still remains the main issue in metastatic CRC patients treated with SBRT. In the oligometastatic setting, SBRT can potentially ablate the whole burden of disease, but more careful selection of patients must be performed[45]. In fact, SBRT is often offered to patients who are usually not eligible for other treatment modalities[1,2,37].
Another retrospective analysis showed excellent promising results in a cohort of 40 patients including 26 with single lung metastases (65%), especially in terms of OS (88% at 1 year, 73% at 2 years), while PFS was 53% at 1 year and 28% at 2 years. Failure at the irradiation site was 7.5% (3 of 56 patients) and the time to progression after SBRT was similar to the surgical series; the typical pattern of failure was intrathoracic progression[41].
Thus, SBRT for CRC oligometastases may be a very good tool for maintaining high local control and good OS rates, especially if the radiation dose is escalated. Previous studies have demonstrated that a higher biologically equivalent dose seems to correlate with higher local control. On the other hand, a higher number of lesions may correlate with lower local control and OS. Comito
[46] demonstrated a correlation between OS and cumulative tumor volume greater than 3 cm.
However, SBRT can result in toxicities. In particular, pulmonary SBRT has a safety profile expressed as moderate acute effects and a characteristic late toxicity pattern, appearing more than 6 mo after the end of treatment, which can be radiologic, secondary to radiation-induced fibrotic changes, and clinical, especially cutaneous erythema and chest wall toxicity (more frequently in terms of chronic neuropathic pain, more rarely as rib fractures). However, various retrospective data have shown that toxicity above grade 3 is extremely rare (mostly G1-G2). In conclusion, stereotactic radiation therapy appears to be a safe and efficient way to treat lung metastases, with very high local control rates, low toxicity and promising PFS in selected oligometastatic patients not suitable for surgical resection.
National and international guidelines (AIOM[47], ESMO[1], and NCCN[48]) agree that radical surgery represents the only potentially curative treatment for lung metastases, and these recommendations are based on retrospective data only. However, guidelines do not clearly define the role of chemotherapy in this setting. In particular, there is no unanimous consensus on the best timing or on the preferred drug regimen.
Based on the literature and clinical experience, the choice of chemotherapy treatment can be assessed using several variables: patient (performance status, age, comorbidities) and tumor characteristics (RAS/BRAF status, site of the primary tumor right
left, synchronous
metachronous disease), and resectability status of metastases (resectable
potentially resectable
unresectable)[49,50]. In the scenario of single pulmonary metastases from CRC, the multidisciplinary team, composed of oncologists, thoracic surgeons, radiologists, and radiotherapists, plays a crucial role in outlining adequate personalized treatment planning.
In the context of single resectable pulmonary metastases, the “perfect” timing of the surgical approach is debated. “Oncological” prognostic criteria and “technical” surgical criteria should define the adequate strategy (upfront surgery eventually followed by postoperative chemotherapy or perioperative chemotherapy)[51,52]. Based on such results, patients with unfavorable prognostic factors could be considered for perioperative or postoperative chemotherapy to improve their outcome. In contrast, the presence of positive prognostic factors can allow upfront surgery.
The role of perioperative chemotherapy for single resectable pulmonary metastases is controversial due to the absence of prospective randomized trials. Perioperative therapy aims to increase the R0 metastasectomy rate and decrease the possibility of postoperative relapse, with a subsequent improvement in OS. A meta-analysis of eight retrospective studies investigated the role of perioperative chemotherapy in mCRC patients with radically resected lung metastases. Out of 1936 patients with colorectal lung metastases, 926 underwent surgery alone, while 1010 patients also received perioperative chemotherapy. This meta-analysis demonstrated the benefit of perioperative treatment both in terms of OS (HR 0.83, 95%CI: 0.75-0.92,
< 0.05) and PFS/recurrence-free survival (RFS)/disease-free survival (DFS) (HR 0.67, 95%CI: 0.53-0.86,
< 0.05) compared with surgery alone. Multivariate analysis also confirmed these results (OS: HR 0.56, 95%CI: 0.36-0.86,
< 0.05; PFS/RFS/DFS: HR 0.64, 95%CI: 0.46-0.87,
< 0.05)[53].
The role of postoperative therapy is also debated as no randomized study has compared postoperative therapy after lung metastasectomy
surgery alone. A meta-analysis of 18 cohort studies involving 3885 patients with colorectal lung metastases evaluated the role of postoperative chemotherapy after radical lung resection compared to surgery alone. Postoperative treatment did not improve OS (HR 0.78; 95%CI: 0.60-1.03,
= 0.077) and DFS (HR 0.91; 95%CI: 0.74-1.11,
= 0.339) in comparison to surgery alone. However, it is necessary to underline the important limits of this metaanalysis, mainly the retrospective nature of the studies and the high heterogeneity, which may have negatively affected these results[54].
Another interesting argument is the outcome considering the patient’s oncological history, which may be extremely various considering the timing of lung metastases appearance, concomitant liver involvement and disease-free intervals after CRC treatment. As we reported in previous paragraphs, multidisciplinary evaluation is fundamental, especially in the case of multi-organ involvement. In particular, patients with a history of extra-thoracic metastases[61,68-70] had a worse prognosis similar to patients with synchronous or bilateral lung involvement[71].
Despite the lack of randomized prospective trials and limited evidence, perioperative or postoperative chemotherapy to treat patients with resectable lung metastases is generally used in clinical practice, particularly for those with unfavorable prognostic factors. The most commonly adopted regimen is monotherapy with fluoropyrimidine or the combination with oxaliplatin (FOLFOX/XELOX). Such recommendations are mainly derived from data on mCRC patients with liveronly disease[55].
Miles s hero, and the person he most admired, was country singer Garth Brooks5. Miles would just sit and stare at Garth s picture. One day, Mr. Brooks was traveling from LaGuardia to Nashville and was relaxing in the lounge waiting for his flight to depart. As he looked at the collection of photographs for any new additions, Garth inquired about the youngster with the big smile. We told him about Miles and the fact that he was currently recuperating6 from yet another procedure at Ronald McDonald. We also told him how much Miles loved and admired him.
In the case of potentially resectable lung metastases, induction chemotherapy has, as the main objective, maximal tumor shrinkage to achieve radical resection. In this setting, the preferred treatment regimen corresponds to the most effective first-line therapy for mCRC, which is established based on patient and tumor characteristics. Patients should be re-evaluated regularly every 8-12 wk during therapy and discussed at multidisciplinary meetings to identify the best response and the most appropriate timing of surgery.
Treatment accuracy can be implemented with respiratory gating techniques, with the benefit of reducing the mean radiation dose received by the lungs to avoid pulmonary acute toxicity, but also pulmonary, cardiac, and esophageal late toxicities[42,43]. In addition, magnetic resonance guidance provides excellent visualization of non-bony structures during radiotherapy.
As described in the previous paragraph, the role of adjuvant therapies after lung metastasectomy is a debated and interesting issue, but presents discordant data and remarkable bias in patient selection. Indeed, some studies are in favor of adjuvant therapy (AT) administration[57,58], and others report disadvantages after AT administration[59,60].
The focal point is that it is difficult to consider a homogeneous population, considering the primitive tumor site, number of lung or extra-pulmonary surgically treated metastases and previous administered treatments. Moreover, the lack of clear prognostic factors may lead to a case-by-case decision on AT in advanced stage patients, and its role remains debated and requires clarification in appropriate prospective studies.
Regarding its potential use in patients with operated single metastases, very few data are present in the literature. Rapicetta
[61] did not report any survival advantage when AT was administered, while Guerrera
[62] reported a better outcome when adjuvant chemotherapy was performed in patients with multiple metastases suggesting that no robust data on single metastases are available. The authors confirmed their theories in a recent best evidence topic which showed that AT may improve the prognosis in specific patients with advanced disease or a particular molecular pattern[63].
At first the King and all the kingdom were terrified. All except the Princess, that is. She trusted her littlest knight and upon hearing the whole story set about immediately to make a healing salve for the dragon s eyes.
Based on these reports, clear evidence of AT benefits in patients who underwent lung metastasectomy for single localization is not present, suggesting this therapy especially in patients with multiple metastases. However, further planned research is needed for a better definition of this issue.
Further improvements in radiological differential diagnosis (primary lung tumor
mCRC) could be obtained from radiomics and its application on chest CT-scan or PET-CT scan.
The CEA levels are routinely analyzed during follow-up in CRC patients, and it is interesting to note that they may also have a prognostic role in patients with lung metastases, by determining the worse prognosis in patients with CEA levels > 4-5 ng/mL (Table 1). The primitive tumor site does not seem to be associated with prognosis, with only the study by Cavallaro
[64] reporting a better survival rate in the case of right sided tumors
left sided rectal neoplasms. Conversely, the primitive CRC stage resulted in an important prognostic factor, with a poor prognosis in the case of advanced T-stage, presence of neighboring organ invasion or metastases to the loco-regional lymph nodes (Table 1).
It is interesting to note that lymph node spreading seems to be a significant prognostic factor in the case of mediastinal involvement, with various authors reporting that thoracic nodal involvement could be an important prognostic factor for worse long-term outcome[47,65]. Welter and co-workers[66] reported significantly poorer median survival for patients with nodal involvement than for patients without (≈ 30 mo
86 mo). This may also be a factor in the decision-making process to decide whether a patient is suitable for a surgical intervention or not[67], although the same authors caution that even some patients with intra-thoracic lymph node metastases have a longer OS with surgery than with chemotherapy alone[66].
I held the Coke bottle tightly, fearful he would make me pour it into a cup, ruining this dream come true. He didn t. One long swallow of the cold beverage21 cooled my sweating body. I don t think I ever felt so proud.
She was the loveliest young princess, red and white, like milk and blood, with clear blue eyes and golden hair, but right in the middle of her forehead there was a little tuft of brown hair
Four-dimensional (4D)-CT delineates the internal target volume contouring a gross tumor volume, which includes the tumor position in all respiratory cycles and is then expanded with a 3 mm isotropic margin to create the planning treatment volume (PTV); finally, a volumetric modulated arch therapy is planned with a specific treatment planning system. Stereotactic radiotherapy is delivered using a linear accelerator with an energy ranging from 6 to 10 MV photons. During each treatment session, cone-beam CT are performed to verify correct positioning of the patient and the correspondence of the PTV with the target volume identified during the simulation and planning phases[41].
Despite no robust evidence being available on this topic to date, hilo/mediastinal lymph node sampling (at least) is advisable during pulmonary metastasectomy from CRC, especially when enlarged lymph nodes (at CT-scan) or uptake (at 18F-FDG PET-CT scan) by lymph nodes are detectable. There are no articles specifically focused on single pulmonary metastases, but oncological principles and indications are also applicable and valid in this scenario.
Tumor dimension, with a cut-off of 2 cm, is another well analyzed parameter in these patients, valid in the presence of single but also multiple metastases[61].
Then a big fire was lit again, and the mother said: Just sit down there, children, and if you re tired you can sleep a bit; we re going into the forest to cut down wood, and in the evening when we re finished we ll come back to fetch you
Finally, the DNA fragmentation index (DFI) between CRC treatment and lung metastases appearance is another validated prognostic factor, even if a universal cut-off is not present in the literature. Indeed, a better prognosis stratification is present when the DFI is evaluated at > 6[72], > 12[61,73], or 36 mo[67,74,75] confirming that a long DFI is an important factor when considering treatment for lung metastases from CRC.
A promising factor may be the metabolic activity of the nodule which was found to be a significant prognostic factor in the study by Rapicetta
[61] and Davini
[76]. In detail, Davini
[76] reported that PET negativity was a protective factor for OS (HR 0.46;
= 0.001; 95%CI: 0.29-0.72) and for DFI after lung metastasectomy, while Rapicetta
[61] reported that PET positivity in single CRC metastases (RR: 2.702, 95%CI: 1.041-7.013,
= 0.041) was a negative independent prognostic factor only for DFI.
With regard to long-term outcome, 5-year OS after single metastasis resection ranged between 32% and 62%[61,71,77], but it is interesting to note that the best survival rates (around 60% at 5 years) were reported in recent studies[61,71] suggesting a progressive improvement in terms of therapeutic strategies, but also regarding more accurate patient selection. The presence of a single metastases was one of the most important prognostic factors in surgically treated patients (Table 1), which was also confirmed in a meta-analysis by Gonzalez
[78], who demonstrated a favorable prognostic role for the number of resected metastases, which was a significant favorable factor associated with CEA levels, DFI, and presence of lymph node involvement. In detail, the authors reported a significantly increased mortality risk in the case of multiple metastases: HR 2.04, 95%CI: 1.72-2.41. On the other hand, very few data are available regarding prognostic factors in this class of patients with single metastases.
Metastasis dimension seems to be significantly related with survival in these patients, with survival improvement in patients with a metastasis dimension less than 2 cm. In particular, Nanji
[79] reported an unadjusted 5-year CSS and OS of 57% and 55%, respectively, for single lesions smaller than 2 cm, and 33% for a single lesion exceeding 2 cm, in agreement with previously published results[61].
Only Rapicetta
[61] performed a more accurate survival analysis in these patients and demonstrated that advanced age and elevated pre-thoracotomy CEA levels were also associated with poor survival. Moreover, the authors analyzed prognostic factors for DFS after metastasectomy and showed that a short DFI between colorectal resection and lung resection (cut-off 12 mo) increased PET uptake and the presence of synchronous lung metastasis were predictive of a short DFS. A long DFS was also found to be a protective factor by Davini
[76], but also included multiple metastases.
On the other hand, the radiation dose and fractionation schedule are chosen based on several factors, such as tumor size, tumor location and neighboring organs at risk of dose constraints. In most of the clinical trials, SBRT was delivered in a few fractions (3-10), while single fraction SBRT has been less investigated and, in general, the dose administered is between 24 and 65 Gy in total. Moreover, the low number of treatment fractions may also play a role in the activation of an anti-tumor immune response because, in addition to damaging and killing cancer cells, radiation can destroy the adjacent tumor protective stromal microenvironment[39,40].
Finally, Cavallaro
[64] reported a significantly better survival rate when lung metastases were not associated with liver metastases.
Based on these reported studies, CEA pre-thoracotomy levels and short DFI may be evaluated when treating these patients, considering that the prognosis may be poor and a careful advantages/ disadvantages analysis should consider the patient’s general condition and surgical risks.
Recurrence after lung metastasectomy is common, ranging between 32.9% and 72%[62,70,73,80] with lung involvement present in about 50% of cases[81] and with a redo surgery rate of about 50%[73].
48. Kind heaven help us now!: Gretel prays for heavenly assistance. Once again, these religious references were added by the Grimms.Return to place in story.
When technically feasible and in patients able to tolerate a repeated lung resection, the surgical approach seems to ensure interesting results in terms of survival, with 5-year OS ranging between 49% and 76.3%[62,69,78].
In 26 patients with recurrence, Fukada
[69] reported a 5-year OS of 76.9%, while Menna
[82] did not report a survival difference when comparing patients who underwent single or repeated lung metastasectomy. Ogata reported a significantly better survival in patients who underwent repeated resection in the case of single metastases without extra-thoracic disease[80]; however, CEA level, number of pulmonary metastases, mediastinal lymph node metastasis, and DFI also seem to be related to survival after repeat pulmonary metastasectomy[80,83-85].
However, this excellent survival outcome might be linked to careful patient selection indicating that the surgical approach in patients with limited lung involvement and good performance status may reduce the risks of redo-surgery in these patients. Conversely, repeated surgery may be carefully considered in patients with nodal or extra-thoracic metastases and sub-optimal clinical conditions.
Single pulmonary metastasis from CRC is an uncommon scenario with diagnostic pitfalls to be considered. Loco-regional approaches (surgery more than radiotherapy or ablative procedures) may have a potential curative role with rewarding long-term results. However, the absence of randomized prospective trials and limited data availability does not permit definitive conclusions. Chemotherapy, including timing and drug regimen, should be evaluated on a case-by-case basis by the multidisciplinary team by considering both tumor and patient characteristics.
The best long-term results may be expected when integrating loco-regional with systemic treatment. Despite evidence being limited, different factors seem to influence prognosis in this subset of patients and should be considered when planning a tailored care strategy.
5. Bremen: Bremen is located in northwest Germany. It was a Free Hanseatic League City after the end of the Old German Empire and became part of the German Alliance in 1815 (Bremen Tourism, Free ). It is a harbor city but couldn t serve large ships because of silt21 clogging22 the river (Bremen Tourism, Free ). This lead to the creation of Bremerhaven in 1827 (Bremen Tourism, Free ). The city is famous for its statue of Roland, which was erected23 in 1404 (Bremen Tourism, Free ).
Then she began to say, Why should I not marry? But she wanted a husband who could answer when he was spoken to, not one who would stand up stiffly and look respectable--that would be too dull
The Queen went home quite satisfied, and thought she had got rid of her step-children; but the girl had not run to meet her with her brothers, and she knew nothing of her
We would like to thank Franziska M Lohmeyer, PhD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, for her support revising our manuscript language.
Chiappetta M wrote the paper; Congedo MT, Petracca Ciavarella L, Bensi M, De Luca V and Camarda F collected the bibliography and supported manuscript drafting; Evangelista J supported manuscript drafting; Salvatore L and Lococo F revised and edited the manuscript; Margaritora S, Tortorta G and Valentini V supervised the manuscript.
No conflict-of-interest to declare.
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Italy
Marco Chiappetta 0000-0002-3807-6911; Lisa Salvatore 0000-0003-3864-0719; Maria teresa Congedo 0000-0001-5563-0331; Maria Bensi 0000-0002-5647-0525; Viola De Luca 0000-0002-9914-0075; Leonardo Petracca Ciavarella 0000-0002-9659-1014; Floriana Camarda 0000-0002-5206-6867; Jessica Evangelista 0000-0001-6707-6120; Vincenzo Valentini
0000 -0003-4637-6487; Giampaolo Tortora 0000-0002-1378-4962; Stefano Margaritora 0000-0002-9796-760X; Filippo Lococo 0000-0002-9383-5554.
Zhang H
Webster JR
Zhang H
1 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, K?hne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, ?sterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Ta?eb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
2016; 27: 1386-1422 [PMⅠD: 27380959 DOⅠ: 10.1093/annonc/mdw235]
2 Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna Ⅰ, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. NCCN Guidelines Ⅰnsights: Colon Cancer, Version 2.2018.
2018; 16: 359-369 [PMⅠD: 29632055 DOⅠ: 10.6004/jnccn.2018.0021]
3 Ehrenhaft JL, Lawrence MS, Sensenig DM. Pulmonary resections for metastatic lesions.
1958; 77: 606-612 [PMⅠD: 13582418 DOⅠ: 10.1001/archsurg.1958.04370010138013]
4 Bray F, Ferlay J, Soerjomataram Ⅰ, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
2018; 68: 394-424 [PMⅠD: 30207593 DOⅠ: 10.3322/caac.21492]
5 Brody H. Colorectal cancer.
2015; 521: S1 [PMⅠD: 25970450 DOⅠ: 10.1038/521S1a]
6 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020.
2020; 70: 7-30 [PMⅠD: 31912902 DOⅠ: 10.3322/caac.21590]
7 Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020.
2020; 70: 145-164 [PMⅠD: 32133645 DOⅠ: 10.3322/caac.21601]
8 Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR, Winchester DP. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
2017; 67: 93-99 [PMⅠD: 28094848 DOⅠ: 10.3322/caac.21388]
9 Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, Mahar AL, Patel T, Sargent DJ, Weiser MR, Compton C; members of the AJCC Precision Medicine Core. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine.
2016; 66: 370-374 [PMⅠD: 26784705 DOⅠ: 10.3322/caac.21339]
10 Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study.
2010; 59: 1383-1388 [PMⅠD: 20732912 DOⅠ: 10.1136/gut.2010.211557]
11 Li Y, Zhou Z, Liu D, Zhou M, Tan F, Liu W, Zhu H. Predictive and Prognostic Factors of Synchronous Colorectal Lung-Limited Metastasis.
2020; 2020: 6131485 [PMⅠD: 33299406 DOⅠ: 10.1155/2020/6131485]
12 Tan KK, Lopes Gde L Jr, Sim R. How uncommon are isolated lung metastases in colorectal cancer?
2009; 13: 642-648 [PMⅠD: 19082673 DOⅠ: 10.1007/s11605-008-0757-7]
13 Parnaby CN, Bailey W, Balasingam A, Beckert L, Eglinton T, Fife J, Frizelle FA, Jeffery M, Watson AJ. Pulmonary staging in colorectal cancer: a review.
2012; 14: 660-670 [PMⅠD: 21689294 DOⅠ: 10.1111/j.1463-1318.2011.02601.x]
14 Brent A, Talbot R, Coyne J, Nash G. Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer?
2007; 9: 816-818 [PMⅠD: 17931171 DOⅠ: 10.1111/j.1463-1318.2007.01229.x]
15 Kronawitter U, Kemeny NE, Heelan R, Fata F, Fong Y. Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma.
1999; 86: 229-235 [PMⅠD: 10421258]
16 Grossmann I, Avenarius JK, Mastboom WJ, Klaase JM. Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure.
2010; 17: 2045-2050 [PMⅠD: 20151212 DOⅠ: 10.1245/s10434-010-0962-y]
17 Collie DA, Wright AR, Williams JR, Hashemi-Malayeri B, Stevenson AJ, Turnbull CM. Comparison of spiral-acquisition computed tomography and conventional computed tomography in the assessment of pulmonary metastatic disease.
1994; 67: 436-444 [PMⅠD: 8193888 DOⅠ: 10.1259/0007-1285-67-797-436]
18 Ohtaki Y, Shimizu K, Nagashima T, Nakazawa S, Obayashi K, Azuma Y, Ⅰijima M, Kosaka T, Yajima T, Ogawa H, Tsutsumi S, Arai M, Mogi A, Kuwano H. Clinical and Radiological Discrimination of Solitary Pulmonary Lesions in Colorectal Cancer Patients.
2018; 42: 1161-1170 [PMⅠD: 28983707 DOⅠ: 10.1007/s00268-017-4243-9]
19 Reinhardt MJ, Wiethoelter N, Matthies A, Joe AY, Strunk H, Jaeger U, Biersack HJ. PET recognition of pulmonary metastases on PET/CT imaging: impact of attenuation-corrected and non-attenuation-corrected PET images.
2006; 33: 134-139 [PMⅠD: 16193313 DOⅠ: 10.1007/s00259-005-1901-1]
20 Jess P, Seiersen M, Ovesen H, Sandstr?m H, Maltb?k N, Buhl AA, Roikj?r O. Has PET/CT a role in the characterization of indeterminate lung lesions on staging CT in colorectal cancer?
2014; 40: 719-722 [PMⅠD: 24462549 DOⅠ: 10.1016/j.ejso.2013.11.030]
21 Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna Ⅰ, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
2021; 19: 329-359 [PMⅠD: 33724754 DOⅠ: 10.6004/jnccn.2021.0012]
22 Yu X, Song X, Zhu L, Chen W, Dai D, Li X, Xu W. Role of
F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Newly Found Suspected Malignant Solitary Pulmonary Lesions in Patients Who Have Received Curative Treatment for Colorectal Cancer.
2017; 2017: 3458739 [PMⅠD: 28487728 DOⅠ: 10.1155/2017/3458739]
23 Cho WK, Choi DH, Park HC, Park W, Yu JⅠ, Park YS, Park JO, Lim HY, Kang WK, Kim HC, Cho YB, Yun SH, Lee WY. Elevated CEA is associated with worse survival in recurrent rectal cancer.
2017; 8: 105936-105941 [PMⅠD: 29285304 DOⅠ: 10.18632/oncotarget.22511]
24 Treasure T, Farewell V, Macbeth F, Monson K, Williams NR, Brew-Graves C, Lees B, Grigg O, Fallowfield L; PulMiCC Trial Group. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial.
2019; 20: 718 [PMⅠD: 31831062 DOⅠ: 10.1186/s13063-019-3837-y]
25 van Dorp M, Beck N, Steup WH, Schreurs WH. Surgical treatment of pulmonary metastases in the Netherlands: data from the Dutch Lung Cancer Audit for Surgery.
2020; 58: 768-774 [PMⅠD: 32282876 DOⅠ: 10.1093/ejcts/ezaa090]
26 Rotolo N, De Monte L, Ⅰmperatori A, Dominioni L. Pulmonary resections of single metastases from colorectal cancer.
2007; 16 Suppl 1: S141-S144 [PMⅠD: 18037287 DOⅠ: 10.1016/j.suronc.2007.10.007]
27 Kim JY, Park ⅠJ, Kim HR, Kim DK, Lee JL, Yoon YS, Kim CW, Lim SB, Lee JB, Yu CS, Kim JC. Post-pulmonary metastasectomy prognosis after curative resection for colorectal cancer.
2017; 8: 36566-36577 [PMⅠD: 28402263 DOⅠ: 10.18632/oncotarget.16616]
28 Gonzalez M, Zellweger M, Nardini M, Migliore M. Precision surgery in lung metastasectomy.
2020; 16: 7-13 [PMⅠD: 31858825 DOⅠ: 10.2217/fon-2018-0713]
29 Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series.
2007; 84: 324-338 [PMⅠD: 17588454 DOⅠ: 10.1016/j.athoracsur.2007.02.093]
30 Riquet M, Foucault C, Cazes A, Mitry E, Dujon A, Le Pimpec Barthes F, Médioni J, Rougier P. Pulmonary resection for metastases of colorectal adenocarcinoma.
2010; 89: 375-380 [PMⅠD: 20103301 DOⅠ: 10.1016/j.athoracsur.2009.10.005]
31 Greenwood A, West D. Ⅰs a thoracotomy rather than thoracoscopic resection associated with improved survival after pulmonary metastasectomy?
2013; 17: 720-724 [PMⅠD: 23832919 DOⅠ: 10.1093/icvts/ivt300]
32 Meng D, Fu L, Wang L, Dai Y, Lv W, Zhang J, Hu J. Video-assisted thoracoscopic surgery versus open thoracotomy in pulmonary metastasectomy: a meta-analysis of observational studies.
2016; 22: 200-206 [PMⅠD: 26590306 DOⅠ: 10.1093/icvts/ivv309]
33 Shiono S, Okumura T, Boku N, Hishida T, Ohde Y, Sakao Y, Yoshiya K, Hyodo Ⅰ, Mori K, Kondo H. Outcomes of segmentectomy and wedge resection for pulmonary metastases from colorectal cancer.
2017; 51: 504-510 [PMⅠD: 27773868 DOⅠ: 10.1093/ejcts/ezw322]
34 Rolle A, Pereszlenyi A, Koch R, Richard M, Baier B. Ⅰs surgery for multiple lung metastases reasonable?
2006; 131: 1236-1242 [PMⅠD: 16733151 DOⅠ: 10.1016/j.jtcvs.2005.11.053]
35 Lococo F, Cesario A, Ricchetti T, Rapicetta C, Paci M, Sgarbi G. Erratum to: Lung Tissue Damage Caused by Heat Accumulation from Adjacent Laser Application: Surgical Ⅰmplications.
2014; 62: e2 [PMⅠD: 25415626 DOⅠ: 10.1055/s-0034-1394168]
36 Stefani A, Oricchio F, Cinquepalmi A, Aramini B, Morandi U. Ⅰs laser-assisted resection preferable to lobectomy for pulmonary metastasectomy?
2020; 35: 611-620 [PMⅠD: 31410616 DOⅠ: 10.1007/s10103-019-02856-8]
37 Lococo F, Ⅰaffaldano A, Zanfrini E, Pogliani L, Tabacco D, Sassorossi C, Mazzarella C, Margaritora S. Thulium cyber laser-assisted uniportal thoracoscopic resection of a pulmonary metastasis from colorectal cancer.
2020; 75: 475-477 [PMⅠD: 33006450 DOⅠ: 10.23736/S0026-4733.20.08416-3]
38 Ricardi U, Badellino S, Filippi AR. Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach.
2016; 57: i58-i68 [PMⅠD: 26962198 DOⅠ: 10.1093/jrr/rrw006]
39 Kobiela J, Spychalski P, Marvaso G, Ciardo D, Dell'Acqua V, Kraja F, B?a?yńska-Spychalska A, ?achiński AJ, Surgo A, Glynne-Jones R, Jereczek-Fossa BA. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review.
2018; 129: 91-101 [PMⅠD: 30097241 DOⅠ: 10.1016/j.critrevonc.2018.06.005]
40 Filippi AR, Guerrera F, Badellino S, Ceccarelli M, Castiglione A, Guarneri A, Spadi R, Racca P, Ciccone G, Ricardi U, Ruffini E. Exploratory Analysis on Overall Survival after Either Surgery or Stereotactic Radiotherapy for Lung Oligometastases from Colorectal Cancer.
2016; 28: 505-512 [PMⅠD: 26899780 DOⅠ: 10.1016/j.clon.2016.02.001]
41 Filippi AR, Badellino S, Ceccarelli M, Guarneri A, Franco P, Monagheddu C, Spadi R, Ragona R, Racca P, Ricardi U. Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a singleinstitution cohort study.
2015; 91: 524-529 [PMⅠD: 25542308 DOⅠ: 10.1016/j.ijrobp.2014.10.046]
42 Kini VR, Vedam SS, Keall PJ, Patil S, Chen C, Mohan R. Patient training in respiratory-gated radiotherapy.
2003; 28: 7-11 [PMⅠD: 12747612 DOⅠ: 10.1016/S0958-3947(02)00136-X]
43 Giraud P, Morvan E, Claude L, Mornex F, Le Pechoux C, Bachaud JM, Boisselier P, Beckendorf V, Morelle M, Carrère MO; STⅠC Study Centers. Respiratory gating techniques for optimization of lung cancer radiotherapy.
2011; 6: 2058-2068 [PMⅠD: 22052228 DOⅠ: 10.1097/JTO.0b013e3182307ec2]
44 Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F, Franceschini D, Navarria P, Reggiori G, Tomatis S, Scorsetti M. Predictive factors for survival of oligometastatic colorectal cancer treated with Stereotactic body radiation therapy.
2019; 133: 220-226 [PMⅠD: 30414754 DOⅠ: 10.1016/j.radonc.2018.10.024]
45 Franzese C, Comito T, Franceschini D, Loi M, Clerici E, Navarria P, De Rose F, Di Brina L, Mancosu P, Reggiori G, Tomatis S, Scorsetti M. Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
2020; 146: 1227-1234 [PMⅠD: 32056005 DOⅠ: 10.1007/s00432-020-03148-3]
46 Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarria P, Ascolese A, Tozzi A, Ⅰftode C, De Rose F, Villa E, Personeni N, Rimassa L, Santoro A, Fogliata A, Mancosu P, Tomatis S, Scorsetti M. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.
2014; 14: 619 [PMⅠD: 25163798 DOⅠ: 10.1186/1471-2407-14-619]
47 Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD. Management of metastatic colorectal cancer patients: guidelines of the Ⅰtalian Medical Oncology Association (AⅠOM).
2017; 2: e000147 [PMⅠD: 28761730 DOⅠ: 10.1136/esmoopen-2016-000147]
48 Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
2017; 15: 370-398 [PMⅠD: 28275037 DOⅠ: 10.6004/jnccn.2017.0036]
49 Meimarakis G, Spelsberg F, Angele M, Preissler G, Fertmann J, Crispin A, Reu S, Kalaitzis N, Stemmler M, Giessen C, Heinemann V, Stintzing S, Hatz R, Winter H. Resection of pulmonary metastases from colon and rectal cancer: factors to predict survival differ regarding to the origin of the primary tumor.
2014; 21: 2563-2572 [PMⅠD: 24668147 DOⅠ: 10.1245/s10434-014-3646-1]
50 Suzuki H, Kiyoshima M, Kitahara M, Asato Y, Amemiya R. Long-term outcomes after surgical resection of pulmonary metastases from colorectal cancer.
2015; 99: 435-440 [PMⅠD: 25499475 DOⅠ: 10.1016/j.athoracsur.2014.09.027]
51 Lee WS, Yun SH, Chun HK, Lee WY, Yun HR, Kim J, Kim K, Shim YM. Pulmonary resection for metastases from colorectal cancer: prognostic factors and survival.
2007; 22: 699-704 [PMⅠD: 17109105 DOⅠ: 10.1007/s00384-006-0218-2]
52 Onaitis MW, Petersen RP, Haney JC, Saltz L, Park B, Flores R, Rizk N, Bains MS, Dycoco J, D'Amico TA, Harpole DH, Kemeny N, Rusch VW, Downey R. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases.
2009; 87: 1684-1688 [PMⅠD: 19463577 DOⅠ: 10.1016/j.athoracsur.2009.03.034]
53 Li Y, Qin Y. Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis.
2020; 146: 545-553 [PMⅠD: 32036456 DOⅠ: 10.1007/s00432-020-03142-9]
54 Zhang C, Tan Y, Xu H. Does adjuvant chemotherapy improve the prognosis of patients after resection of pulmonary metastasis from colorectal cancer?
2019; 34: 1661-1671 [PMⅠD: 31446479 DOⅠ: 10.1007/s00384-019-03362-7]
55 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Ⅰntestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Ⅰntestinal Trials Group (AGⅠTG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
2013; 14: 1208-1215 [PMⅠD: 24120480 DOⅠ: 10.1016/S1470-2045(13)70447-9]
56 Andres A, Mentha G, Adam R, Gerstel E, Skipenko OG, Barroso E, Lopez-Ben S, Hubert C, Majno PE, Toso C. Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases.
2015; 102: 691-699 [PMⅠD: 25789941 DOⅠ: 10.1002/bjs.9783]
57 Rusch VW. Pulmonary metastasectomy. Current indications.
1995; 107: 322S-331S [PMⅠD: 7781414 DOⅠ: 10.1378/chest.107.6_supplement.322s]
58 Higashiyama M, Kodama K, Takami K, Higaki N, Yokouchi H, Nakayama T, Murata K, Kameyama M, Ashimura J, Naruse Y, Nagumo S. Ⅰntraoperative lavage cytologic analysis of surgical margins as a predictor of local recurrence in pulmonary metastasectomy.
2002; 137: 469-474 [PMⅠD: 11926957 DOⅠ: 10.1001/archsurg.137.4.469]
59 Higashiyama M, Tokunaga T, Nakagiri T, Ⅰshida D, Kuno H, Okami J. Pulmonary metastasectomy: outcomes and issues according to the type of surgical resection.
2015; 63: 320-330 [PMⅠD: 25836329 DOⅠ: 10.1007/s11748-015-0544-9]
60 Shiono S, Ⅰshii G, Nagai K, Yoshida J, Nishimura M, Murata Y, Tsuta K, Kim YH, Nishiwaki Y, Kodama T, Ⅰwasaki M, Ochiai A. Predictive factors for local recurrence of resected colorectal lung metastases.
2005; 80: 1040-1045 [PMⅠD: 16122482 DOⅠ: 10.1016/j.athoracsur.2004.12.033]
61 Rapicetta C, Lococo F, Davini F, Carleo F, Kauppi J, Di Stefano TS, Ricciardi S, Di Martino M, R?s?nen J, Paci M, Melfi F, Cardillo G. Ⅰs Adjuvant Chemotherapy Worthwhile After Radical Resection for Single Lung Metastasis From Colorectal Cancer?
2019; 9: 763 [PMⅠD: 31482063 DOⅠ: 10.3389/fonc.2019.00763]
62 Guerrera F, Mossetti C, Ceccarelli M, Bruna MC, Bora G, Olivetti S, Lausi PO, Solidoro P, Ciccone G, Ruffini E, Oliaro A, Filosso PL. Surgery of colorectal cancer lung metastases: analysis of survival, recurrence and re-surgery.
2016; 8: 1764-1771 [PMⅠD: 27499967 DOⅠ: 10.21037/jtd.2016.05.98]
63 Guerrera F, Falcoz PE, Renaud S, Massard G. Does perioperative chemotherapy improve survival in patients with resectable lung metastases of colorectal cancer?
2017; 24: 789-791 [PMⅠD: 28453801 DOⅠ: 10.1093/icvts/ivw389]
64 Cavallaro P, Bordeianou L, Stafford C, Clark J, Berger D, Cusack J, Kunitake H, Francone T, Ricciardi R. Ⅰmpact of Single-organ Metastasis to the Liver or Lung and Genetic Mutation Status on Prognosis in Stage ⅠV Colorectal Cancer.
2020; 19: e8-e17 [PMⅠD: 31899147 DOⅠ: 10.1016/j.clcc.2019.12.001]
65 Renaud S, Alifano M, Falcoz PE, Magdeleinat P, Santelmo N, Pagès O, Massard G, Régnard JF. Does nodal status influence survival?
2014; 18: 482-487 [PMⅠD: 24442624 DOⅠ: 10.1093/icvts/ivt554]
66 Welter S, Jacobs J, Krbek T, Poettgen C, Stamatis G. Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer.
2007; 31: 167-172 [PMⅠD: 17150367 DOⅠ: 10.1016/j.ejcts.2006.11.004]
67 Cho JH, Kim S, Namgung M, Choi YS, Kim HK, Zo JⅠ, Shim YM, Kim J. The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer.
2015; 13: 222 [PMⅠD: 26205014 DOⅠ: 10.1186/s12957-015-0621-7]
68 Zabaleta J, Ⅰida T, Falcoz PE, Salah S, Jarabo JR, Correa AM, Zampino MG, Matsui T, Cho S, Ardissone F, Watanabe K, Gonzalez M, Gervaz P, Emparanza JⅠ, Abraira V. Ⅰndividual data meta-analysis for the study of survival after pulmonary metastasectomy in colorectal cancer patients: A history of resected liver metastases worsens the prognosis.
2018; 44: 1006-1012 [PMⅠD: 29602524 DOⅠ: 10.1016/j.ejso.2018.03.011]
69 Fukada M, Matsuhashi N, Takahashi T, Tanaka Y, Okumura N, Yamamoto H, Shirahashi K, Ⅰwata H, Doi K, Yoshida K. Prognostic factors in pulmonary metastasectomy and efficacy of repeat pulmonary metastasectomy from colorectal cancer.
2020; 18: 314 [PMⅠD: 33256771 DOⅠ: 10.1186/s12957-020-02076-3]
70 Sakamaki Y, Ⅰshida D, Tanaka R. Prognosis of patients with recurrence after pulmonary metastasectomy for colorectal cancer.
2020; 68: 1172-1178 [PMⅠD: 32323124 DOⅠ: 10.1007/s11748-020-01368-5]
71 Fournel L, Maria S, Seminel M, Nesci J, Mansuet-Lupo A, Guinet C, Magdeleinat P, Bobbio A, Regnard JF, Alifano M. Prognostic factors after pulmonary metastasectomy of colorectal cancers: a single-center experience.
2017; 9: S1259-S1266 [PMⅠD: 29119012 DOⅠ: 10.21037/jtd.2017.04.44]
72 Hwang MR, Park JW, Kim DY, Chang HJ, Kim SY, Choi HS, Kim MS, Zo JⅠ, Oh JH. Early intrapulmonary recurrence after pulmonary metastasectomy related to colorectal cancer.
2010; 90: 398-404 [PMⅠD: 20667318 DOⅠ: 10.1016/j.athoracsur.2010.04.058]
73 Takakura Y, Miyata Y, Okajima M, Okada M, Ohdan H. Short disease-free interval is a significant risk factor for intrapulmonary recurrence after resection of pulmonary metastases in colorectal cancer.
2010; 12: e68-e75 [PMⅠD: 19843115 DOⅠ: 10.1111/j.1463-1318.2009.02070.x]
74 Rama N, Monteiro A, Bernardo JE, Eugénio L, Antunes MJ. Lung metastases from colorectal cancer: surgical resection and prognostic factors.
2009; 35: 444-449 [PMⅠD: 19136273 DOⅠ: 10.1016/j.ejcts.2008.10.047]
75 Yedibela S, Klein P, Feuchter K, Hoffmann M, Meyer T, Papadopoulos T, G?hl J, Hohenberger W. Surgical management of pulmonary metastases from colorectal cancer in 153 patients.
2006; 13: 1538-1544 [PMⅠD: 17009154 DOⅠ: 10.1245/s10434-006-9100-2]
76 Davini F, Ricciardi S, Zirafa CC, Romano G, Alì G, Fontanini G, Melfi FMA. Correction to: Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study.
2020; 35: 371-372 [PMⅠD: 31838578 DOⅠ: 10.1007/s00384-019-03485-x]
77 Pfannschmidt J, Muley T, Hoffmann H, Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients.
2003; 126: 732-739 [PMⅠD: 14502146 DOⅠ: 10.1016/s0022-5223(03)00587-7]
78 Gonzalez M, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: systematic review and meta-analysis.
2015; 11: 31-33 [PMⅠD: 25662325 DOⅠ: 10.2217/fon.14.259]
79 Nanji S, Karim S, Tang E, Brennan K, McGuire A, Pramesh CS, Booth CM. Pulmonary Metastasectomy for Colorectal Cancer: Predictors of Survival in Routine Surgical Practice.
2018; 105: 1605-1612 [PMⅠD: 29518384 DOⅠ: 10.1016/j.athoracsur.2018.02.007]
80 Ogata Y, Matono K, Hayashi A, Takamor S, Miwa K, Sasatomi T, Ⅰshibashi N, Shida S, Shirouzu K. Repeat pulmonary resection for isolated recurrent lung metastases yields results comparable to those after first pulmonary resection in colorectal cancer.
2005; 29: 363-368 [PMⅠD: 15706447 DOⅠ: 10.1007/s00268-004-7537-7]
81 Murakawa T. Past, present, and future perspectives of pulmonary metastasectomy for patients with advanced colorectal cancer.
2021; 51: 204-211 [PMⅠD: 32857252 DOⅠ: 10.1007/s00595-020-02119-y]
82 Menna C, Berardi G, Tierno SM, Andreetti C, Maurizi G, Ciccone AM, D'Andrilli A, Cassiano F, Poggi C, Diso D, Venuta F, Rendina EA, Ⅰbrahim M. Do Repeated Operations for Recurrent Colorectal Lung Metastases Result in Ⅰmproved Survival?
2018; 106: 421-427 [PMⅠD: 29605599 DOⅠ: 10.1016/j.athoracsur.2018.02.065]
83 Kanzaki R, Higashiyama M, Oda K, Fujiwara A, Tokunaga T, Maeda J, Okami J, Tanaka K, Shingai T, Noura S, Ohue M, Kodama K. Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma.
2011; 202: 419-426 [PMⅠD: 21824604 DOⅠ: 10.1016/j.amjsurg.2010.08.016]
84 Hachimaru A, Maeda R, Suda T, Takagi Y. Repeat pulmonary resection for recurrent lung metastases from colorectal cancer: an analysis of prognostic factors.
2016; 22: 826-830 [PMⅠD: 26920721 DOⅠ: 10.1093/icvts/ivv382]
85 Chen F, Sakai H, Miyahara R, Bando T, Okubo K, Date H. Repeat resection of pulmonary metastasis is beneficial for patients with colorectal carcinoma.
2010; 34: 2373-2378 [PMⅠD: 20582543 DOⅠ: 10.1007/s00268-010-0695-x]
86 Shiomi K, Naito M, Sato T, Nakamura T, Nakashima H, Mikubo M, Matsui Y, Watanabe M, Satoh Y. Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer.
2017; 20: 19-25 [PMⅠD: 28702182 DOⅠ: 10.1016/j.amsu.2017.06.026]
87 Imanishi M, Yamamoto Y, Hamano Y, Yamada T, Moriwaki T, Gosho M, Okumura T, Boku N, Kondo H, Hyodo Ⅰ. Efficacy of adjuvant chemotherapy after resection of pulmonary metastasis from colorectal cancer: a propensity scorematched analysis.
2019; 106: 69-77 [PMⅠD: 30471650 DOⅠ: 10.1016/j.ejca.2018.10.003]
88 Tsitsias T, Toufektzian L, Routledge T, Pilling J. Are there recognized prognostic factors for patients undergoing pulmonary metastasectomy for colorectal carcinoma?
2016; 23: 962-969 [PMⅠD: 27572615 DOⅠ: 10.1093/icvts/ivw273]
89 Zampino MG, Maisonneuve P, Ravenda PS, Magni E, Casiraghi M, Solli P, Petrella F, Gasparri R, Galetta D, Borri A, Donghi S, Veronesi G, Spaggiari L. Lung metastases from colorectal cancer: analysis of prognostic factors in a single institution study.
2014; 98: 1238-1245 [PMⅠD: 25106681 DOⅠ: 10.1016/j.athoracsur.2014.05.048]
90 Tampellini M, Ottone A, Bellini E, Alabiso Ⅰ, Baratelli C, Bitossi R, Brizzi MP, Ferrero A, Sperti E, Leone F, Miraglia S, Forti L, Bertona E, Ardissone F, Berruti A, Alabiso O, Aglietta M, Scagliotti GV. The role of lung metastasis resection in improving outcome of colorectal cancer patients: results from a large retrospective study.
2012; 17: 1430-1438 [PMⅠD: 22956535 DOⅠ: 10.1634/theoncologist.2012-0142]
91 Landes U, Robert J, Perneger T, Mentha G, Ott V, Morel P, Gervaz P. Predicting survival after pulmonary metastasectomy for colorectal cancer: previous liver metastases matter.
2010; 10: 17 [PMⅠD: 20525275 DOⅠ: 10.1186/1471-2482-10-17]
World Journal of Gastrointestinal Oncology2022年4期